CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Icosapent ethylWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (4)


Name (Synonyms) Correlation
drug1548 NA-831and Dexamethasone Wiki 1.00
drug1547 NA-831 and Atazanavir Wiki 1.00
drug235 Atazanavir and Dexamethasone Wiki 1.00
drug794 Drug: NA-831 Wiki 1.00

Correlated MeSH Terms (5)


Name (Synonyms) Correlation
D012141 Respiratory Tract Infections NIH 0.21
D003141 Communicable Diseases NIH 0.09
D007239 Infection NIH 0.06
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0011947 Respiratory tract infection HPO 0.21

There is one clinical trial.

Clinical Trials


1 An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19 (VASCEPA-COVID-19)

This is a 14-day long prospective, multi-site, two-armed, randomized, open-label study that will enroll approximately 100 adult outpatients in Canada who have received a positive SARS-CoV-2 test result within the preceding 72 hours. Participants will be randomized (1:1) to receive either icosapent ethyl (4 g BID for 3 days, then 2 g BID for the subsequent 11 days) or usual care. Blood samples will be collected to determine if icosapent ethyl use lowers circulating pro-inflammatory biomarkers.

NCT04412018 COVID-19 Inflammatory Response Drug: Icosapent ethyl

Primary Outcomes

Measure: Change in hs-CRP levels from the randomization visit (Day 1) to the Day 14 visit

Time: 14 days

Secondary Outcomes

Measure: Change in D-dimer levels from the randomization visit (Day 1) to the Day 14 visit

Time: 14 days

Measure: Change in erythrocyte sedimentation rate from the randomization visit (Day 1) to the Day 14 visit

Time: 14 days

Measure: Change in complete blood count from the randomization visit (Day 1) to the Day 14 visit

Time: 14 days

Measure: Change in differential count from the randomization visit (Day 1) to the Day 14 visit

Time: 14 days

Measure: Change in serum albumin levels from the randomization visit (Day 1) to the Day 14 visit

Time: 14 days

Measure: Change in neutrophil-to-lymphocyte ratio (NLR) from the randomization visit (Day 1) to the Day 14 visit

Time: 14 days

Measure: Change in systemic immune-inflammation index from the randomization visit (Day 1) to the Day 14 visit

Time: 14 days

Other Outcomes

Description: Response options will be along one of the following formats: (i) 5-point Likert scale with answers ranging from (a) "Not at all" to "Very much" and (b) "Never" to "Always" (ii) Quantitative with answers ranging from "0 times" or "4 or more times" (iii) Binary response format (Yes or No)

Measure: Change in FLU-PRO scores from the screening visit to the Day 14 visit

Time: 14 days

Description: Response options will range from 0 to 6 with a higher value indicating a worse outcome

Measure: World Health Organization Symptom Severity Scale

Time: 14 days


No related HPO nodes (Using clinical trials)